drugset / Trial / NCT00002599

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

NCT00002599

Phase 3 Unknown 750 enrolled Medical Research Council
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining bone marrow or peripheral stem cell transplantation with chemotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether a more intensive chemotherapy regimen plus stem cell or bone marrow transplant is more effective than standard chemotherapy in treating patients with myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy plus interferon alfa with or without high dose melphalan or bone marrow or peripheral stem cell transplantation in treating patients with previously untreated myeloma.

Timeline

Start
1994-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified
Subject Doxorubicin Other / unclassified
Subject Melphalan Small molecule
Subject Methylprednisolone Other / unclassified
Subject Prednisone Other / unclassified
Subject Vincristine Small molecule
Subject carmustine Small molecule
Background filgrastim Protein / enzyme biologic
Background interferon alfa-2b Protein / enzyme biologic
Background sargramostim Protein / enzyme biologic

Indications